Compare CCSI & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCSI | ABEO |
|---|---|---|
| Founded | 2021 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.6M | 399.5M |
| IPO Year | 2022 | 2005 |
| Metric | CCSI | ABEO |
|---|---|---|
| Price | $37.46 | $7.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $37.50 | $20.00 |
| AVG Volume (30 Days) | 141.0K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $349,696,000.00 | $2,998,000.00 |
| Revenue This Year | $3.33 | $1,024.31 |
| Revenue Next Year | $2.70 | $145.42 |
| P/E Ratio | $29.51 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $19.42 | $4.00 |
| 52 Week High | $41.40 | $7.54 |
| Indicator | CCSI | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 76.10 |
| Support Level | $35.92 | $4.85 |
| Resistance Level | $41.40 | N/A |
| Average True Range (ATR) | 1.82 | 0.36 |
| MACD | -0.13 | 0.11 |
| Stochastic Oscillator | 42.65 | 97.27 |
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.